ProfileGDS5678 / 1426820_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 89% 89% 89% 89% 90% 90% 90% 90% 90% 89% 90% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9465689
GSM967853U87-EV human glioblastoma xenograft - Control 27.0254789
GSM967854U87-EV human glioblastoma xenograft - Control 36.9826189
GSM967855U87-EV human glioblastoma xenograft - Control 47.1290389
GSM967856U87-EV human glioblastoma xenograft - Control 57.1489789
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7338989
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9422390
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2184990
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2180190
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.147390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.137990
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1391389
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2926990
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3760191